Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers

The microarray batches will be used in multicenter, clinical validation studies of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.